Interesting facts
Interesting Facts about 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
This compound is a fascinating example of a complex organic molecule that exhibits both pharmaceutical and biochemical significance. Its structure combines multiple functional groups that suggest a potential for versatile biological activity.
Key Features
- Hydroxymethyl and Hydroxy Groups: The presence of both hydroxymethyl and hydroxy groups contributes to its ability to form hydrogen bonds, which can enhance solubility and interaction with biological targets.
- Hexylamino Chain: The hexylamino portion of the molecule indicates potential lipophilicity, which may influence its transport within biological systems. This property can be particularly advantageous for drug delivery applications.
- Phenylbutoxy Moiety: The inclusion of a phenylbutoxy segment may help in modulating the pharmacological properties of the compound, potentially offering improved efficacy or selectivity towards specific receptors.
Pharmaceutical Applications
This compound may be considered in the design of novel pharmaceuticals. Its unique combination of hydroxy, amine, and ether functionalities makes it a prime candidate for:
- Antineoplastic agents
- Antimicrobial preparations
- Neurological drug formulations
Quote from the Field
As one prominent chemist stated, "The beauty of organic chemistry lies in the complexity and connectivity of small molecules. Each addition of functional groups can drastically change a compound's behavior, from solubility to biological interaction."
Conclusion
The study of 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol highlights the importance of structure-function relationships in organic compounds. Continued research on its properties and applications could lead to exciting discoveries in therapeutic development.
Synonyms
Salmeterol
89365-50-4
Serevent
Astmerole
Aeromax
Salmeterolum [Latin]
Salmeterolum
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
GR 33343X
SALMATEROL
SN408D
HSDB 7315
UNII-2I4BC502BT
GR 33343 X
2I4BC502BT
DTXSID6023571
GR-33343-X
2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol
(+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol
DTXCID803571
CHEBI:64064
Salmeterolum (Latin)
1,3-Benzenedimethanol, 4-hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-
4-(1-hydroxy-2-(6-(4-phenylbutoxy)hexylamino)ethyl)-2-(hydroxymethyl)phenol
2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol
4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)-2-(hydroxymethyl)phenol
SMR000466295
SR-01000076139
Salmeterol (USAN/INN)
Salmeterol [USAN:INN:BAN]
Salmeterol?
(rs)-salmeterol
Salmeterolxinafoate
NCGC00025247-01
(+-)-salmeterol
3-Benzenedimethanol, 4-hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-; 1,3-Benzenedimethanol, 4-hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (+/-)-; GR 33343X; Salmeterol; GR 33343X
4-hydroxy-alpha1-
(+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol
CPD000466295
SALMETEROL [MI]
SALMETEROL [INN]
Prestwick3_000945
SALMETEROL [HSDB]
SALMETEROL [USAN]
SALMETEROL [VANDF]
S 2692
SCHEMBL4767
CHEMBL1263
SALMETEROL [WHO-DD]
Lopac0_001100
BSPBio_000910
GTPL559
MLS000759000
MLS001424322
(+/-)-4-hydroxy-alpha1-
BPBio1_001002
CHEBI:9011
Salmeterol Xinafoate Impurity 1
BDBM25771
MSK1377
R03AC12
HMS2052H13
HMS2090E17
HMS2097N12
HMS3268K19
HMS3394H13
HMS3412P13
HMS3714N12
HMS3886G10
BCP04199
EX-A4409
Tox21_113584
MFCD00867037
s5527
STK629186
AKOS005561914
CCG-101194
CCG-205176
DB00938
FS46783
NC00444
SDCCGSBI-0633788.P001
1,3-Benzenedimethanol, 4-hydroxy-.alpha.1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-
MRF-0000468
NCGC00015938-03
NCGC00025247-02
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl-, (+-)-
AS-56157
HY-14302
Salmeterol 100 microg/mL in Acetonitrile
CAS-89365-50-4
DB-226688
AB00513972
NS00010340
C07241
C77008
D05792
AB00513972-07
EN300-18530979
L000532
Q424333
SR-01000076139-2
SR-01000076139-6
BRD-A01320529-001-05-9
BRD-A01320529-104-10-1
BRD-A01320529-104-11-9
BRD-A01320529-104-12-7
2-hydroxymethyl-4-{1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl}phenol
(RS)-4-hydroxy-alpha(1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol
2-(Hydroxymethyl)-4-[(1R)-1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]a mino}ethyl]phenol
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]-phenol
( inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; GR 33343X
(+-)-4-hydroxy-alpha(1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha(1)-diol
1-hydroxy-2-naphthoic acid;4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]-2-methylol-phenol
Solubility of 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
The solubility of the compound 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol (C24H26N2O4) is influenced by several key factors:
In general, solubility can also be assessed by the following factors:
In conclusion, understanding the solubility of C24H26N2O4 requires consideration of its unique structural features and environmental conditions. Solubility is a pivotal factor in determining the applicability of this compound in various formulations and applications.